top of page
NOVAPEP IS DEVELOPING ANTI-INFLAMMATORY AND CYTOPROTECTIVE PEPTIDE STRUCTURES TO TREAT UNMET NEEDS
home page bg 1.png

THE  COMPANY.

Novapep is an Australian-US biotech peptide therapeutic company which is developing analogs of its NVP-202 agonist peptide structure, which mimics the cell-signalling mechanisms of Activated Protein C.
home page bg 2.png

THE SCIENCE.

Human Activated Protein C ('APC') has been shown to be effective in animal models of numerous diseases and conditions.  Scientists at the Scripps Research Institute have developed a bivalent agonist peptide structure which mimics the cell signalling activities of APC.  NVP-202 has demonstrated anti-inflammatory, cytoprotective and endothelial barrier protection in a number of pre-clinical published studies.
Based on highly promising preclinical data in sepsis, Novapep is developing modified forms NVP-202 to significantly increase the half-life and bioavailability of the structure, for the treatment of sepsis and sepsis-associated acute kidney injury ('SA-AKI') and other indications. 

 PROGRAMS.

NOVAPEP_Icon_Type_White_Transparent.png
bottom of page